Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; the references it cites are not checked yet; 18 of the 85 sources its claims cite were checked for support.

Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations

Open access

Abstract

BACKGROUND: Antidepressant exposure during pregnancy has been associated with an increased risk of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in several observational studies. We performed a systematic review of these studies to highlight the effect that important methodological limitations have on such analyses and to consider approaches to the conduct, reporting and interpretation of future studies. METHODS: A review of MEDLINE and EMBASE identified case-control, cohort and sibling studies assessing the risk of ASD and ADHD with antidepressant use during pregnancy. Approaches to confounding adjustment were described. Crude and adjusted effect estimates for comparisons between antidepressant exposure during pregnancy vs. all unexposed women were first meta-analysed using a generic inverse variance method of analysis, followed by effect estimates for alternative pre-selected comparison groups. RESULTS: A total of 15 studies measuring ASD as an outcome (involving 3,585,686 children and 40,585 cases) and seven studies measuring ADHD as an outcome (involving 2,765,723 patients and 52,313 cases) were identified. Variation in confounding adjustment existed between studies. Updated effect estimates for the association between maternal antidepressant exposure during pregnancy vs. all unexposed women remained statistically significant for ASD (adjusted random-effects risk ratio [RaRR] 1.53, 95% confidence interval [CI] 1.31-1.78). Similar significant associations were observed using pre-pregnancy maternal antidepressant exposure (RaRR 1.48, 95% CI 1.29-1.71) and paternal antidepressant exposure during pregnancy (1.29, 95% CI 1.08-1.53), but analyses restricted to using women with a history of affective disorder (1.18, 95% CI 0.91-1.52) and sibling studies (0.96, 95% CI 0.65-1.42) were not statistically significant. Corresponding associations for risk of ADHD with exposure were: RaRR 1.38, 95% CI 1.13-1.69 (during pregnancy), RaRR 1.38, 95% CI 1.14-1.69 (during pre-pregnancy), RaRR 1.71, 95% CI 1.31-2.23 (paternal exposure), RaRR 0.98, 95% CI 0.77-1.24 (women with a history of affective disorder) and RaRR 0.88, 95% CI 0.70-1.11 (sibling studies). CONCLUSIONS: Existing observational studies measuring the risk of ASD and ADHD with antidepressant exposure are heterogeneous in their design. Classical comparisons between exposed and unexposed women during pregnancy are at high risk of residual confounding. Alternative comparisons and sibling designs may aid the interpretation of causality and their utility requires further evaluation, including understanding potential limitations of undertaking meta-analyses with such data.

Overview

CoChat Summary

## TL;DR

This systematic review of 15 ASD studies and 7 ADHD studies found that the classic comparison of antidepressant-exposed vs all unexposed pregnancies showed statistically significant associations, but alternative comparisons and sibling designs generally did not. The authors conclude that residual confounding, especially confounding by indication and depression severity, likely explains much of the association.

## Key findings

  • For ASD, 15 studies included 3,585,686 children and 40,585 cases; the pooled adjusted random-effects risk ratio for maternal antidepressant exposure during pregnancy vs all unexposed women was 1.53 (95% CI 1.31–1.78).
  • For ADHD, 7 studies included 2,765,723 patients and 52,313 cases; the pooled adjusted random-effects risk ratio for maternal antidepressant exposure during pregnancy vs all unexposed women was 1.38 (95% CI 1.13–1.69).
  • Alternative comparisons were not statistically significant in several cases: for ASD, women with a history of affective disorder had RaRR 1.18 (95% CI 0.91–1.52) and sibling studies RaRR 0.96 (95% CI 0.65–1.42); for ADHD, women with a history of affective disorder had RaRR 0.98 (95% CI 0.77–1.24) and sibling studies RaRR 0.88 (95% CI 0.70–1.11).
  • Paternal antidepressant exposure during pregnancy was also associated with increased risk in pooled analyses: ASD RaRR 1.29 (95% CI 1.08–1.53) and ADHD RaRR 1.71 (95% CI 1.31–2.23).

## Methods

  • Systematic review of observational studies published on or before May 2017, searching MEDLINE and EMBASE; eligible designs were case–control, cohort, and sibling studies.
  • Included studies assessed ASD and ADHD outcomes after antidepressant exposure during pregnancy; data were extracted on study design, comparators, sample size, confounder adjustment, and crude/adjusted effect estimates.
  • Crude and adjusted effect estimates were pooled using a generic inverse variance method with random-effects models; fixed-effect models, leave-one-out analyses, and sensitivity analyses by comparator group and study design were also performed.

## Limitations

  • The paper states that observational studies are limited by unmeasured confounding, especially confounding by indication and severity of depression, and by heterogeneity in confounding adjustment across studies.
  • It also states that outcome coding in administrative databases may cause misclassification, and that pre-pregnancy exposure may not have been cleanly separated from continued pregnancy exposure in all studies.
  • Evident from the text: some alternative comparator groups had few studies/effect estimates, limiting inference; the authors also note they did not contact study authors and their search was limited to the databases used.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12916-017-0993-3

Cites

Statistics

Nothing to recompute.

Figures

Fig. 1 PRISMA (Preferred Reporting Items for Systematic Reviews) flow diagram for study selection. ADHD attention deficit hyperactivity disorder, ASD autism spectrum disorder
Fig. 1 PRISMA (Preferred Reporting Items for Systematic Reviews) flow diagram for study selection. ADHD attention deficit hyperactivity disorder, ASD autism spectrum disorderCC BY · PubMed Central
Fig. 2 Risk of autism spectrum disorder associated with maternal antidepressant exposure during pregnancy compared to unexposed women. CI confidence interval, df degrees of freedom, SE standard error of the mean
Fig. 2 Risk of autism spectrum disorder associated with maternal antidepressant exposure during pregnancy compared to unexposed women. CI confidence interval, df degrees of freedom, SE standard error of the meanCC BY · PubMed Central
Fig. 3 Risk of autism spectrum disorder associated with pre-pregnancy maternal antidepressant exposure during pregnancy compared to unexposed women. CI confidence interval, df degrees of freedom, SE standard error of the mean
Fig. 3 Risk of autism spectrum disorder associated with pre-pregnancy maternal antidepressant exposure during pregnancy compared to unexposed women. CI confidence interval, df degrees of freedom, SE standard error of the meanCC BY · PubMed Central
Fig. 4 Risk of autism spectrum disorder associated with maternal antidepressant exposure during pregnancy compared to unexposed women with a history of affective disorder. CI confidence interval, df degrees of freedom, SE standard error of the mean
Fig. 4 Risk of autism spectrum disorder associated with maternal antidepressant exposure during pregnancy compared to unexposed women with a history of affective disorder. CI confidence interval, df degrees of freedom, SE standard error of the meanCC BY · PubMed Central
Fig. 5 Risk of attention deficit hyperactivity disorder associated with maternal antidepressant exposure during pregnancy compared to unexposed women. CI confidence interval, df degrees of freedom, SE standard error of the mean
Fig. 5 Risk of attention deficit hyperactivity disorder associated with maternal antidepressant exposure during pregnancy compared to unexposed women. CI confidence interval, df degrees of freedom, SE standard error of the meanCC BY · PubMed Central
Fig. 6 Risk of attention deficit hyperactivity disorder associated with pre-pregnancy maternal antidepressant exposure during pregnancy compared to unexposed women. CI confidence interval, df degrees of freedom, SE standard error of the mean
Fig. 6 Risk of attention deficit hyperactivity disorder associated with pre-pregnancy maternal antidepressant exposure during pregnancy compared to unexposed women. CI confidence interval, df degrees of freedom, SE standard error of the meanCC BY · PubMed Central
Fig. 7 Risk of attention deficit hyperactivity disorder associated with maternal antidepressant exposure during pregnancy using a sibling study design. CI confidence interval, df degrees of freedom, SE standard error of the mean
Fig. 7 Risk of attention deficit hyperactivity disorder associated with maternal antidepressant exposure during pregnancy using a sibling study design. CI confidence interval, df degrees of freedom, SE standard error of the meanCC BY · PubMed Central

Verification

Claims the paper makes

3 Valid · 1 Not valid · 23 Not checked · 88 Own results and interpretations

58 more claims

Create a free account to see all 115 claims and to verify the 67 references still open.

See all claims — free account
  • It may state two separate claims as one. 27
  • Probably not a substantial claim. 31

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 49 · Cited by 118

Research works printed but not linked: 1

  1. CIOMS Working Group X. Evidence synthesis and meta-analysis, Chapter 3. 2016.

Metadata

Authors
Morales, D. R., Slattery, J., Evans, S., & Kurz, X.
Affiliations
  • European Medicines Agency (NL)
  • University of London (GB)
Corresponding author
Morales, Daniel R.
Venue
BMC Medicine
Published
2018-01-15
Volume
16
Issue
1
Pages
6-6
ISSN
1741-7015 (ISSN-L)
OpenAlex
W2783908905
Cited by
118
References
49
Citations by year
2026: 8 · 2025: 5 · 2024: 11 · 2023: 14 · 2022: 18 · 2021: 16 · 2020: 21 · 2019: 20 · 2018: 5
FWCI
2.82
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (acceptedVersion, cc-by)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
Keywords
autism spectrum disorder, attention deficit hyperactivity disorder, maternal antidepressant use, confounding adjustment, mood disorders, prenatal drug exposure, reporting quality, sibling studies, confounding by indication
MeSH terms
Autism Spectrum Disorder, Adult, Antidepressive Agents, Attention Deficit Disorder with Hyperactivity, Child, Female, Humans, Male, Pregnancy, Pregnancy Complications, Prenatal Exposure Delayed Effects, Risk Factors, Cohort Studies, Epidemiologic Research Design, Case-Control Studies, Mood Disorders, Young Adult, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations. https://app.cochat.ai/papers/10.1186/s12916-017-0993-3
The paper
Morales, D. R., Slattery, J., Evans, S., & Kurz, X. (2018). Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations. BMC Medicine. https://doi.org/10.1186/s12916-017-0993-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.